Structure-based discovery and experimental validation of HIT101481851 as a potential PKMYT1 inhibitor for pancreatic cancer

TL;DR

This study identifies a new compound, HIT101481851, that may effectively target PKMYT1 to treat pancreatic cancer.

Contribution

The paper introduces HIT101481851 as a novel PKMYT1 inhibitor with strong binding and anticancer properties.

Findings

HIT101481851 showed favorable binding to PKMYT1 residues like CYS-190 and PHE-240.

The compound inhibited pancreatic cancer cell viability in a dose-dependent manner.

ADMET predictions suggest good absorption and low toxicity for HIT101481851.

Abstract

PKMYT1 is a validated therapeutic target in pancreatic cancer due to its critical role in controlling the G2/M transition of the cell cycle. In this study, a structure-based drug discovery pipeline was implemented to identify novel PKMYT1 inhibitors with high binding stability and anticancer potential. Pharmacophore models were constructed from four PKMYT1 co-crystal structures, and virtual screening was performed against a large compound library. Through molecular docking and intersection analysis, five consensus high-affinity compounds were identified, among which HIT101481851 demonstrated the most favorable binding characteristics. Molecular dynamics simulations confirmed its stable interactions with key residues such as CYS-190 and PHE-240 across multiple PKMYT1 conformations. ADMET predictions indicated good gastrointestinal absorption, acceptable drug-likeness, and low risk of off-target reactivity. Furthermore, in vivo experiments showed that HIT101481851 inhibited the viability of pancreatic cancer cell lines in a dose-dependent manner while exhibiting lower toxicity toward normal pancreatic epithelial cells. These results suggest that HIT101481851 is a promising lead compound for the development of PKMYT1-targeted therapeutics in pancreatic cancer.

Figures